Annual report pursuant to Section 13 and 15(d)

Agreements (Details)

v3.19.1
Agreements (Details)
 1 Months Ended 12 Months Ended
Feb. 16, 2018
USD ($)
unit
$ / unit
Sep. 22, 2016
USD ($)
Dec. 18, 2015
USD ($)
unit
Dec. 01, 2014
kg
May 31, 2011
May 19, 2008
USD ($)
Aug. 31, 2018
USD ($)
Nov. 30, 2017
USD ($)
$ / unit
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2013
USD ($)
Oct. 31, 2017
Asset Acquisition And License Agreement [Line Items]                        
Other commitment                 $ 6,000,000      
Noncontrolling interest ownership percentage by Noncontrolling Owners                       10.00%
Cost of product sales                 7,478,262 $ 635,648    
Ulesfia Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
License obligation current                 7,800,000      
Escrow deposit disbursement                 1,900,000      
Cost of product sales                 2,200,000      
Indemnity receivable                 4,900,000      
Lilly | License Agreement To Develop Transmembrane Ampa Receptor Regulatory Proteins                        
Asset Acquisition And License Agreement [Line Items]                        
Asset acquisition payments   $ 2,000,000                    
Potential milestone commitment due within 30 days   $ 750,000                    
Time period within execution of license agreement   30 days                    
Potential milestone commitment due after first subject closed   $ 1,250,000                    
Merck | CERC-301                        
Asset Acquisition And License Agreement [Line Items]                        
Other commitment                     $ 750,000  
Merck | CERC-301 | Research and development                        
Asset Acquisition And License Agreement [Line Items]                        
Asset acquisition payments                     750,000  
Merck | COMT Inhibitor                        
Asset Acquisition And License Agreement [Line Items]                        
Asset acquisition payments                     $ 200,000  
TRIS Pharma | Karbinal Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Product royalty 23.50%                      
Contract term 20 years                      
Potential milestone revenue threshold $ 40,000,000                      
Potential milestone payment $ 3,000,000                      
Minimum quantity required | unit 70,000                      
Make whole payment (in dollars per unit) | $ / unit 30                      
Product royalty 15.00%                      
Make whole payment             $ 934,300   $ 1,281,525      
Avadel | Karbinal Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Make whole payment (percent) 8.50%                      
Eisai Inc | AcipHex Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Product royalty 15.00%                      
Potential milestone revenue threshold $ 50,000,000                      
Yung Shin Pharm. Ind, Co | Cefaclor                        
Asset Acquisition And License Agreement [Line Items]                        
Product royalty 15.00%                      
Automatic renewal period 12 months                      
Potential milestone revenue threshold $ 40,000,000                      
TRx | Merck | Metafolin Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Percentage Metafolin requirements contracted to purchase       100.00%                
Product royalty       2.00%                
Purchase commitment minimum mass required | kg       1                
Royalty payment period       45 days                
Contract term       1 year                
TRx | Mead Johnson and Company LLC | Poly-Vi-Flor And Tri-Vi-Flor License                        
Asset Acquisition And License Agreement [Line Items]                        
Product royalty       10.00%                
Royalty payment period       45 days                
TRx | Presmar Associates | Poly-Vi-Flor Trademark                        
Asset Acquisition And License Agreement [Line Items]                        
Product royalty         5.00%              
Royalty payment period         45 days              
TRx | Watson Laboratories | License And Supply Agreement For Millipred Tablets                        
Asset Acquisition And License Agreement [Line Items]                        
Contract term           5 years            
Automatic renewal period           1 year            
Semi-annual license payment           $ 75,000            
Zylera | Ulesfia Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Price per unit (in dollars per unit) | $ / unit               58.84        
Management and handling fee (in dollars per unit) | $ / unit               3.66        
Management and handling fee annual price increase               10.00%        
Zylera | Lachlan Pharmaceuticals | Ulesfia Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Minimum royalty     $ 3,000,000                  
Minimum quantity required | unit     20,000                  
Long-term purchase commitment     $ 1,200,000                  
Consecutive periods within twelve months orders unfilled     6 months                  
Periods within twelve months orders unfilled     9 months                  
Purchase commitment measurement period     12 months                  
Indemnification of post-acquisition losses, (as a percent)                 50.00%      
Lachlan Pharmaceuticals | Ulesfia Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Indemnification of pre-acquisition losses               100.00%        
Indemnification of post-acquisition losses, (as a percent)               50.00%        
Minimum | TRx | Merck | Metafolin Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Product target age       0 years                
Minimum | Lachlan Pharmaceuticals | Ulesfia Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Threshold indemnification of legal costs and possible minimum payments               $ 1,000,000        
Maximum | TRIS Pharma | Karbinal Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Make whole payment $ 750,000                      
Maximum | Eisai Inc | AcipHex Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Royalty payment period 5 years                      
Potential milestone payment $ 8,000,000.0                      
Maximum | Yung Shin Pharm. Ind, Co | Cefaclor                        
Asset Acquisition And License Agreement [Line Items]                        
Potential milestone payment $ 6,500,000.0                      
Maximum | TRx | Merck | Metafolin Supply Agreement                        
Asset Acquisition And License Agreement [Line Items]                        
Product target age       3 years